-
JBCRG-S01
Meta-analysis of Abraxane used as a neo-adjuvant chemotherapy for operable breast cancer
- Status
-
Study Closed
- Objectives
-
To investigate the average efficacy rate of Abraxane-containing regimen as a neoadjuvant chemotherapy for breast cancer in Japan based on the following two hypotheses.
For anthracycline and taxane containing regimen as a neoadjuvant chemotherapy, the following two hypotheses are set up.
1.Abraxane as taxane may show a high pCR rate in combination with trastuzumab for HER2-positive breast cancer.
2.Abraxane as taxane may be safe and tolerable for most of patients.
- Subjects
-
- Endpoints
-
Primary: pCR: pathological complete response
Secondary: Adverse events(>=G3) , RDI(Relative dose intensity for Abraxane)
- Trial Period
-
Nov. 2017～Jan. 2019
- Lead Principal Investigator
-
1.Manabu Futamura(Gifu University Hospital ) 2.Mari Oba(Toho University) 3.Norikazu Masuda(National Hospital Organization Osaka Medical Center )
- Target Sample Size
-
- Regimen
-
Abraxane
- Source of Funding
-
TAIHO Pharmaceutical Co., Ltd
- Conference Presentation
-
Meta-analysis of nanoparticle albumin-bound paclitaxel (Nab-PTX) used as a neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01)
- Articles and Publications
-
Meta‑analysis of nanoparticle albumin‑bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG‑S01 study)
- UMIN-ID
-
UMIN000028774
- jRCT
-
- Memo
-
- COI Disclosure
-
